Voyager Therapeutics (VYGR) Tops Q3 EPS by 29c

Voyager Therapeutics (NASDAQ: VYGR) reported Q3 EPS of ($0.16), $0.29 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $24.63 million versus the consensus estimate of $11.7 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• Berenberg Downgrades DKSH Holding AG (DKSH:SW) to Hold
• RBC Capital Downgrades Ansell Ltd. (ANN:AU) (ANSLY) to Sector Perform
• UBS Upgrades Geely Automotive Holdings Ltd. (175:HK) (GELYF) to Buy